Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Review Article

Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy

Abstract

Live cells offer unique advantages as vehicles for systemic oncolytic virus (OV) delivery. Recent studies from our laboratory and others have shown that virus-infected cells can serve as Trojan horse vehicles to evade antiviral mechanisms encountered in the bloodstream, prevent uptake by off-target tissues and act as microscale factories to produce OV upon arrival in tumor beds. However to be employed effectively, OV-infected cells are best viewed as dynamic biological systems rather than static therapeutic agents. The time-dependent processes of infection and in vivo cell trafficking will inevitably vary depending on which particular OV is being delivered, as well as the type of carrier cells (CC) employed. Understanding these parameters with respect to each unique CC/OV combination will therefore be required in order to effectively evaluate and harness their potential in preclinical study. In the following review, we discuss how early studies of OV delivery led us to investigate the use of cell carriers in our laboratory, and the approaches we are currently undertaking to compare the dynamics of different CC/OV systems. On the basis of these studies and others it is apparent that the success of any cell-based system for OV delivery rests upon the coordinated timing of three sequential phases—(1) ex vivo loading, (2) stealth delivery and (3) virus production at the tumor site. While at the current time, the timing of these processes are coupled to the natural cycle of infection and in vivo trafficking properties innate to each cell virus system, a quantitative delineation of their dynamics will lay the foundation for engineering CC/OV biotherapeutic systems that can be clinically deployed in a highly directed and controlled manner.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3

References

  1. Parato KA, Senger D, Forsyth PA, Bell JC . Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965–976.

    CAS  Article  PubMed  Google Scholar 

  2. Liu TC, Galanis E, Kirn D . Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101–117.

    CAS  Article  PubMed  Google Scholar 

  3. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821–825.

    CAS  Article  PubMed  Google Scholar 

  4. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263–275.

    CAS  Article  PubMed  Google Scholar 

  5. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007; 15: 123–130.

    CAS  Article  PubMed  Google Scholar 

  6. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007; 15: 1686–1693.

    CAS  Article  PubMed  Google Scholar 

  7. Fisher K . Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther 2006; 8: 301–313.

    CAS  PubMed  Google Scholar 

  8. Gobet R, Cerny A, Ruedi E, Hengartner H, Zinkernagel RM . The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus. Exp Cell Biol 1988; 56: 175–180.

    CAS  PubMed  Google Scholar 

  9. Leist TP, Cobbold SP, Waldmann H, Aguet M, Zinkernagel RM . Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol 1987; 138: 2278–2281.

    CAS  PubMed  Google Scholar 

  10. Zinkernagel RM, Adler B, Holland JJ . Cell-mediated immunity to vesicular stomatitis virus infections in mice. Exp Cell Biol 1978; 46: 53–70.

    CAS  PubMed  Google Scholar 

  11. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523–1537.

    CAS  PubMed  Google Scholar 

  12. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW . Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Therapy 2007; 14: 324–333.

    CAS  Article  PubMed  Google Scholar 

  13. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007; 15: 114–122.

    CAS  Article  PubMed  Google Scholar 

  14. Thorne SH, Negrin RS, Contag CH . Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311: 1780–1784.

    CAS  Article  PubMed  Google Scholar 

  15. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L . Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755–766.

    CAS  Article  PubMed  Google Scholar 

  16. Hakkarainen T, Sarkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 2007; 18: 627–641.

    CAS  Article  PubMed  Google Scholar 

  17. Raykov Z, Balboni G, Aprahamian M, Rommelaere J . Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004; 109: 742–749.

    CAS  Article  PubMed  Google Scholar 

  18. Garcia-Castro J, Martinez-Palacio J, Lillo R, Garcia-Sanchez F, Alemany R, Madero L et al. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther 2005; 12: 341–349.

    CAS  Article  PubMed  Google Scholar 

  19. Power AT, Bell JC . Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 2007; 15: 660–665.

    CAS  Article  PubMed  Google Scholar 

  20. Bergman I, Whitaker-Dowling P, Gao Y, Griffin JA . Preferential targeting of vesicular stomatitis virus to breast cancer cells. Virology 2004; 330: 24–33.

    CAS  Article  PubMed  Google Scholar 

  21. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ . Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 2005; 65: 5292–5300.

    CAS  Article  PubMed  Google Scholar 

  22. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005; 11: 346–352.

    CAS  Article  PubMed  Google Scholar 

  23. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209–214.

    CAS  Article  PubMed  Google Scholar 

  24. Bucheit AD, Kumar S, Grote DM, Lin Y, von MV, Cattaneo RB et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003; 7: 62–72.

    CAS  Article  PubMed  Google Scholar 

  25. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R . Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 2001; 75: 2087–2096.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ . Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 2003; 101: 2557–2562.

    CAS  Article  PubMed  Google Scholar 

  27. Schuurman HJ, Pierson III RN . Progress towards clinical xenotransplantation. Front Biosci 2008; 13: 204–220.

    CAS  Article  PubMed  Google Scholar 

  28. Huppert J, Gresland L, Lazar P . Heterogeneity of chick embryo cells with regard to Newcastle disease virus multiplication. J Gen Virol 1974; 23: 281–287.

    CAS  Article  PubMed  Google Scholar 

  29. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005; 11: 1073–1081.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J C Bell.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Power, A., Bell, J. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 15, 772–779 (2008). https://doi.org/10.1038/gt.2008.40

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2008.40

Keywords

  • vesicular stomatitis virus
  • oncolytic virus
  • cancer therapeutics
  • immunity
  • cell-based delivery
  • biotherapeutics

Further reading

Search

Quick links